This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Companion Diagnostics Market, 2012-2023

The Companion Diagnostics Market, 2013-2023 report provides an extensive study of the emerging market of companion diagnostics. The report differentiates personalised medicine diagnostics and companion diagnostics; we have separately defined these two closely associated markets and provided our estimates of the market size for each. The report covers various aspects, such as, advantages of personalised medicine over traditional medicine and the need for companion diagnostics.

One of the key objectives of this report is to understand the current state of the companion diagnostics market. This is done by analysing • Products currently available in the market and those under development, • Pharmaceutical and diagnostic companies active in the market, and • Deals and collaborations in the recent years

The market for companion diagnostics has also been evaluated regionally; this provides a greater clarity in the differing approaches various regions have towards personalised medicine and companion diagnostics. In parallel, we have also analysed the market for companion drugs that are associated with companion diagnostics.

The report provides market forecasts for the period 2012 - 2023. We have discussed, in detail, the key drivers behind the regional and global growth. The research, analysis and insights presented in this report include the sales of all companion diagnostic tests that are essential before prescription of any companion drug.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Key Highlights1. The global companion diagnostics market is likely to achieve sales of USD 897 MM by 2018, growing at a compounded annual growth rate (CAGR) of 29.2% from 2012 to 2018.2. In 2011, 41.2% of the new molecular entities (NMEs) were approved with a pharmacogenomic biomarker by the FDA.3. The sales of marketed companion drugs generated estimated revenues of more than USD 22 BN in 2012, with six drugs achieving blockbuster status.4. In terms of value, 95.9% of the sales in the companion drugs market was contributed by drugs indicated for cancer.5. The overall companion drugs market is dominated by three leading companies – Roche Laboratories, Novartis and Pfizer. Together these companies accounted for 61.3% of the companion drugs market in 2012.6. There are several personalised medicine diagnostics in the market, with companion diagnostics constituting its subset. Companion diagnostics represented 10.1% of the personalised medicine diagnostics market in 2012.7. The pipeline for companion diagnostics is rich with most products being developed with the collaborative effort of pharmaceutical and diagnostics companies. Many start-ups diagnostic companies are also engaged in partnership with large pharmaceutical companies for developing companion diagnostic tests.8. The US was the largest market for companion diagnostics in 2012, accounting for 41.0% of the total market.

1. EXECUTIVE SUMMARY1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines1.4. Key Highlights1.4.1. Oncology is the Leading Indication for Companion Drugs1.4.2. Roche is One of the Most Active Companies in the Market1.4.3. Partnership is the Preferred Model for Companion Diagnostics Development1.4.4. US is the Largest Market for Companion Diagnostics1.4.5. Opportunities Outpace the Threats

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,945.73 -138.07 -0.81%
S&P 500 1,978.31 -9.67 -0.49%
NASDAQ 4,447.9820 -24.1260 -0.54%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs